Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

71%

5 of 7 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 3

3(42.9%)

7Total

Phase 2(4)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04630808Phase 3Completed

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Role: lead

NCT05938699Phase 2Completed

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

Role: lead

NCT04445519Phase 3Completed

Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Role: lead

NCT03657797Phase 2Completed

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Role: lead

NCT04675242Phase 2Completed

Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis

Role: lead

NCT03926026Phase 2Completed

Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis

Role: lead

NCT02756624Phase 3Completed

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

Role: lead

All 7 trials loaded